p53 Recombinant Rabbit Monoclonal Antibody [PD01-32]

About this product

Changes in the p53 gene is one of the most common genetic changes associated with cancer, being implicated in a wide range of tumour types. In many types, more than half of the tumours are p53+. Often p53 positivity is correlated with high grade lesions (e.g., carcinoma of breast, prostate and bladder, malignant lymphoma) and poor prognosis. A few tumour types are characterised by strong p53 expression in most cases, e.g., uterine papillary serous carcinoma. In many tumour types (e.g., malignant lymphomas), p53 appear to have prognostic significance , but the data are often conflicting. In dysplastic lesions, e.g., in Barrett's esophagus, p53 expression increases the risk of carcinoma. p53 may be helpful in differentiating between certain reactive and neoplastic lesions, e.g., reactive urothelial changes (patchy and weak) v. urothelial neoplasia (~60% pos.); reactive mesothelial proliferation (~10% pos.) v. malignant mesothelioma (~60% pos.). p53 positivity is a parameter in the identification of tubal intraepithelial carcinoma associated with pelvic serous carcinoma. Tonsil and appendix are the most recommendable external positive and negative tissue controls. As a guideline for an accurate p53 IHC test more than 20% of germinal centre B-cells must show a weak to moderate nuclear staining reaction, while less than 10% of the mantle zone B-cells should be demonstrated in tonsil. In appendix, dispersed epithelial cells in the basal parts of the crypts must show a weak to moderate nuclear staining reaction, while the luminal epithelial cells must be negative. In addition, it has to be emphasized, that stromal cells, lymphocytes and endothelial cells in the clinical samples are essential as internal positive tissue controls especially for carcinomas with TP53 mutations causing absence and loss of p53 expression in the tumour cells.

Specifications

Catalog number

HA721213

Size / count

100 µL

Dry ice

No

Hazardous

No

Discontinued

No

CAS Number

9000-83-3

Product Name Alternative

Antigen NY-CO-13 antibody BCC7 antibody Cellular tumor antigen p53 antibody FLJ92943 antibody LFS1 antibody Mutant tumor protein 53 antibody p53 antibody p53 tumor suppressor antibody P53_HUMAN antibody Phosphoprotein p53 antibody Tp53 antibody Transformation related protein 53 antibody TRP53 antibody Tumor protein 53 antibody Tumor protein p53 antibody Tumor suppressor p53 antibody

Abbreviation

TP53

Swiss Prot

P04637 Human

Cellular Locus

Cytoplasm, Nucleus, Endoplasmic reticulum, Mitochondrion matrix

Host

Rabbit

Species Reactivity

Human

Immunogen

Recombinant full length protein within Human p53.

Isotype

IgG

Conjugation

Non-conjugated

Type

Recombinant Rabbit monoclonal Antibody

Applications

IHC-P

Positive Control

Human stomach cancer tissue, human breast cancer tissue.

Concentration

1 mg/mL

Dilution

IHC-P: 1:1,000-1:2,000

Purity

Protein A affinity purified.

Form

Liquid

Buffer

PBS (pH7.4), 0.1% BSA, 40% Glycerol. Preservative: 0.05% Sodium Azide.

Molecular Weight

Predicted band size: 53 kDa

Storage Conditions

Store at +4°C after thawing. Aliquot store at -20°C. Avoid repeated freeze/thaw cycles.

Recombinant Antibody

Yes